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A HISTOLOGICAL ANALYSIS OF THE ROLE OF A LOX-PP VARIANT IN 
BREAST CANCER, LEUKEMIA, AND LYMPHOPROLIFERATIVE DISEASE 
 
MICHAEL EMMERLING 
ABSTRACT 
Background: In their lifetime, 42% of men and 38% of women will be diagnosed 
with cancer. One of the most prominent cancers in women is breast cancer, 
which represents 14.8% of newly diagnosed cancers. Research has 
demonstrated the importance of the lysyl oxidase (LOX) gene, more specifically 
the lysyl oxidase propeptide (LOX-PP), in the attenuation of breast cancer and in 
mouse xenograft models, making it an important and ongoing area of 
investigation. In recent, unpublished experiments, mice with a variant of LOX-PP 
were treated with 7,12-Dimethylbenz[a]anthracene (DMBA) to induce breast 
cancer. However, some of the treated mice developed poor body conditions 
without any signs of having developed breast cancer. Published studies have 
demonstrated that, following treatment with DMBA, some mice generate 
leukemia or other lymphoproliferative diseases. Research has shown that 
identification of these diseases is possible via histological analyses or 
immunohistochemistry. 
Objective: To determine the cause of poor body conditions in mice treated with 
DMBA that did not develop mammary tumors by histological analyses and 
immunohistochemistry. Additionally, to determine the difference between a 
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variant of LOX-PP (LOX-PPv) knock-in (Ki) and wild type (WT) mice in the 
generation of poor body conditions or leukemia/lymphoproliferative disease. 
Methods: A total of 48 mice, 24 LOX-PPv Ki and 24 WT, were treated with DMBA 
and observed for mammary tumor formation. Body conditions of the mice were 
observed and noted, and liver samples from these mice were obtained and 
analyzed via histological and immunohistochemistry interventions. In 
Hematoxylin & Eosin (H&E) assessments of mice livers, mice were classified as 
normal or as having possible lymphocyte infiltration, mild lymphocyte infiltration, 
or massive lymphocyte infiltration. Staining with the Ki-67 antibody in 
immunohistochemistry allowed for classification of mouse livers as normal or as 
having slightly positive or massively positive expression of the Ki-67 antigen. The 
degree to which each liver sample was positive for both readings was compared 
and further analyzed. 
Results: A total of 9 mice (30.4% of Ki mice and 8.7% of WT mice) displayed 
poor body conditions following DMBA treatment. Of the 9 (7 Ki and 2 WT) mice 
having poor body condition, 2 Ki mice suffered from severe dermatitis. For the 7 
remaining mice, no cause for such poor body conditions was obvious. 6 of these 
mice (85.7%) were diagnosed with leukemia. In all other DMBA-treated mice, 
52.6% of Ki and 23.8% of WT displayed some degree of abnormal lymphocyte 
infiltration in the liver, while a total of 39.1% of the KI mice and 69.6% of the WT 
mice had normal liver histologies. 60.9% of Ki and 45.5% of WT mice displayed 
some degree of positivity for expression of Ki-67. 
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Conclusions: Mice not diagnosed with breast cancer but that were suffering 
from poor body conditions likely had developed leukemia or some other 
lymphoproliferative disease. In the mice not definitively diagnosed with leukemia 
by a pathologist, H&E analyses and immunohistochemistry of the livers showed 
lymphocyte infiltration and cellular proliferation possibly indicative of leukemia., 
but further tests are necessary to confirm this. Furthermore, LOX-PPv Ki mice 
appeared to have a greater likelihood of generating poor body conditions or 
some observable sign of abnormal lymphocyte infiltration in the liver versus their 
WT counterparts when treated with DMBA. 
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INTRODUCTION 
Cancer: by the Numbers 
Cancer is a collection of diseases characterized by aberrant growth and 
dissemination of abnormal cells and is the second most common cause of death 
in the US, behind only heart disease. In total, the American Cancer Society 
(ACS) estimates that approximately 1,658,210 individuals will be diagnosed with 
cancer in 2016, while over the course of a lifetime men in the US have a 42% 
chance and women have a 38% chance of developing cancer. Despite significant 
advancements in cancer detection and treatment, the mortality rate for cancer 
reaches approximately 30% (American Cancer Society, 2016). It is thus important 
for researchers to investigate the mechanisms behind the generation and 
propagation of cancer so that treatments can be formulated to specifically target 
and combat cancer before it progresses to the point of fatality. 
 
Causes and characteristics of cancer 
While some cancers are the result of external factors like tobacco or 
infectious organisms, others can be the result of genetic mutations or other 
health conditions and infectious agents (American Cancer Society, 2016); the 
bacteria Helicobacter pylori, for example, has been implicated in the generation 
of stomach cancer (American Cancer Society, 2016; Hwang et al., 2015). These 
inherited or acquired genetic predispositions can act in combination with external 
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stimuli to result in or increase the likelihood of cancer by allowing for the 
acquisition and subsequent propagation of cancerous traits (American Cancer 
Society, 2016; Hanahan & Weinberg, 2011).  
Debatably the most essential trait of the six “hallmark features” of 
cancerous cells is their ability to proliferate uncontrollably via deregulation of 
normal cell proliferative signals. Normal cells exhibit a controlled and carefully 
regulated cell growth cycle, which promotes and maintains homeostatic 
conditions that are favorable to the essential functioning of tissues and organs 
(Hanahan & Weinberg, 2011). Cancerous cells, on the other hand, hijack and 
thereafter deregulate these signaling pathways in order to proliferative indefinitely 
and disrupt normal biological processes (American Cancer Society, 2016; 
Hanahan & Weinberg, 2011). In addition to uncontrolled cell growth and 
proliferation is the ability of cancerous cells to evade growth suppressors and 
resist cell death. This is often the result of the inactivation of tumor suppressor 
genes, often via somatic or germ-line mutations, which allows cancerous cells to 
avoid senescence or apoptotic signaling and continue to proliferate. Under 
normal cellular conditions, this apoptotic signaling prevents further propagation of 
cells that are structurally compromised or that contain significant damage to DNA 
that might have been acquired via genetic mutations or other external factors 
such as carcinogens or ultraviolet (UV) light (Hanahan & Weinberg, 2011).  
Another hallmark of cancerous cells is the ability of these cells to sustain 
themselves with necessary nutrients and oxygen via angiogenesis. Furthermore, 
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these cells are able propagate and spread via the activation of metastatic 
signaling and pathways that increase cellular invasiveness. Studies have shown 
that these metastatic cancer cells typically develop morphological changes and 
display altered associations with surrounding cells and the extracellular matrix 
(ECM). Especially observable in aggressive carcinomas, cancerous cells often 
exhibit compromised cell-to-ECM interactions and an up-regulation of adhesion 
molecules typically associated with cellular migration seen in embryogenesis and 
inflammation (Hanahan & Weinberg, 2011). Together, these acquired traits 
permit normal cells within the body to become tumorigenic and are ultimately 
detrimental to the health of the host organism (Hanahan & Weinberg, 2011).   
 
Breast cancer: an overview 
Breast cancer is a subset of cancer that represents approximately 14.8% 
of newly diagnosed cancers (American Cancer Society, 2016). As such, breast 
cancers is established as one of the most common cancers in women and 
represents the second most common cause of premature female mortality in 
Western countries (Oeffinger, Fontham, Etzioni, et al., 2015; Zhang et al., 2015). 
Despite its prevalence, recent technological and scientific advances in the 
detection and treatment of breast cancer have resulted in a steady decline of 
mortality rates since 1990 (Oeffinger, Fontham, Etzioni, et al., 2015). There still 
remains, however, a high likelihood of mortality from failed therapeutic 
treatments, which are often the result of metastasis and invasiveness of the 
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cancerous cells (Liu et al., 2012). Studies have found that, of those patients 
diagnosed with breast cancer, 10-15% will develop metastases within three years 
(Chan et al., 2015). Beyond this three-year mark, anywhere from 25-50% of 
patients diagnosed with breast cancer develop metastases, even when the 
primary tumor has been successfully eradicated or removed (Lorusso & Rüegg, 
2012). Formation and progression of these tumor metastases is negatively 
correlated with patient prognosis and survival (Zhang et al., 2015).  
The liver is among one of the more prominent sites of metastasis in many 
cancers, including breast cancer, and is the primary organ of interest in our study 
(Tabariès et al., 2015); other common sites of breast cancer metastases include 
the lung, brain, and bone (Lorusso & Rüegg, 2012). As the liver is responsible for 
a number of vital functions like detoxification and metabolism of nutrients, 
infiltration of metastatic cancerous cells poses a serious threat to the health and 
well-being of affected patients (Lorusso & Rüegg, 2012; McCuskey, 2012). The 
liver is also frequently involved in lymphoproliferative diseases such as 
lymphomas and leukemia (Baumhoer et al., 2008). Though primary hepatic 
lymphomas are rare, the liver is often a secondary site of infiltration for neoplastic 
cells that arise from lymphoproliferative diseases such as B- and T-cell 
lymphomas and Hodgkin’s lymphoma (Baumhoer et al., 2008). It is therefore of 
paramount importance to investigate and identify the mechanisms by which 
breast cancer or other lymphoproliferative diseases metastasize to or manifest 
within the liver or to other organs throughout the body. These advancements 
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could drastically improve patient prognosis by allowing for a more effective and 
focused treatment of the cancer. 
 
Lysyl oxidase: role in cancer  
Lysyl oxidase (LOX) is an important protein in tumor suppression and 
metastasis. It is a copper-dependent amine oxidase that functions to crosslink 
collagens and elastins within the extracellular matrix (ECM), stabilizing collagen 
fibrils and promoting elasticity of elastin in order to preserve tissue integrity 
(Csiszar, 2001; Liu et al., 2012; Nishioka, Eustace, & West, 2012). The LOX 
gene, which encodes the LOX protein, has been isolated and shown to encode a 
50kDa lysyl oxidase proenzyme (Pro-LOX) which is proteolytically cleaved by 
bone morphogenetic protein 1 (BMP1) in the extracellular environment to yield 
the 32kDa LOX enzyme and an 18 kDa propeptide (LOX-PP) (Min et al., 2010; 
Nishioka, Eustace, & West, 2012; Barker, Cox, & Erler, 2012). The enzyme 
portion of LOX is encoded for by the C-terminal end of the LOX gene while the 
variable propeptide region resides within the N-terminal domain (Nishioka, 
Eustace, & West, 2012). 
Studies have demonstrated that this 32kDa C-terminal product, the LOX 
enzyme, is responsible for the stabilization of the ECM (Nishioka, Eustace, & 
West, 2012). Interestingly, aberrant or uncontrolled expression of this LOX 
enzyme has been shown to be localized to pre-metastatic regions in orthotopic 
mouse models, suggesting that this LOX enzyme is conducive to or promotes 
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invasive and metastatic phenotypes (Nishioka, Eustace, & West, 2012; Barker, 
Cox, & Erler, 2012). It is believed that this pathological phenotype arises as a 
result of increased ECM deposition and remodeling, which ultimately creates a 
microenvironment that supports homing of disseminated tumor cells. 
Furthermore, this excessive remodeling of the ECM increases growth factor 
signaling that facilitates the formation and progression of tumors in the 
surrounding tissue (Barker, Cox, & Erler, 2012).  As our understanding of cancer 
as a highly complex organ has developed, this “tumor microenvironment” has 
been elucidated as an area of supreme importance in the understanding of 
tumorigenesis. This tumor microenvironment, as it has been coined by Hanahan, 
is composed of a number of supportive cells in the stroma surrounding the tumor. 
This dynamic support system is composed of cancer associated fibroblasts, 
endothelial cells, pericytes, and immune inflammatory cells that are constantly 
evolving and adapting to support and maintain the tumor (Hanahan & Weinberg, 
2011). 
The LOX gene has also been found to have tumor suppressor function 
(Barker, Cox, & Erler, 2012). Originally referred to as the ras recision gene (rrg) 
(Contente, Kenyon, Rimoldi, & Friedman, 1990), LOX gene expression was 
found to oppose tumor progression through suppression of H-RAS-induced 
transformation of mouse fibroblasts (Barker, Cox, & Erler, 2012). Subsequent 
studies further strengthened the idea that LOX had tumor suppressing properties 
via transfection of antisense LOX gene complementary DNA (cDNA) into normal 
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rat kidney fibroblasts (NRKFs). This ultimately resulted in an increase in the 
formation of tumors in nude mice (Barker, Cox, & Erler, 2012; Giampuzzi et al., 
2001). Despite the general knowledge that the LOX gene had tumor suppressor 
function, the mechanisms by which this was accomplished were not elucidated 
for many years. 
 Recent studies have since attributed this tumor suppressor activity of the 
LOX gene to the highly conserved, N-terminal propeptide domain, the 18 kDa 
LOX-PP (Min et al., 2010; Barker, Cox, & Erler, 2012; Palamakumbura et al., 
2004). Palamakumbura et al., for example, demonstrated that transfection of ras-
transformed cells with LOX-PP inhibited the activation of nuclear factor-κB (NF- 
κB), which has been implicated in neoplastic transformation and aberrant cell 
growth (Min et al., 2007; Barker, Cox, & Erler, 2012; Palamakumbura et al., 
2004; Jeay, Pianetti, Kagan, & Sonenshein, 2003). Further in vitro investigations 
demonstrated that this inhibition of NF-κB activation was via inhibition of the ras-
depedent PI3K/PDK1/Akt signal transduction pathway (Palamakumbura et al., 
2004). In vivo studies later corroborated these findings and further demonstrated 
the ability of LOX-PP to revert the invasive phenotype of Her-2/neu-driven cancer 
cells in mouse xenograft models (Min et al., 2007). Correspondingly, LOX-PP 
was found to reduce signaling via PI3K/Akt and MAPK/Erk pathways, as well as 
to reduce downstream NF-κB activity (Min et al., 2007). LOX-PP is the primary 
region of interest for our experiments on the generation and propagation of 
breast cancer and other lymphoproliferative diseases in mice. 
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LOX-PP Variant: Arg158Gln substitution 
Follow-up studies on the protective effects of LOX-PP have found that a single 
nucleotide polymorphism (SNP, rs1800449), which causes a restriction fragment 
length polymorphism (RFLP) (Csiszar et al., 1993), in the N-terminal LOX-PP 
domain impairs the proteins tumor suppressor activity (Min et al., 2009). In 
humans, this SNP results in an Arg158Gln substitution within a highly conserved 
region of LOX-PP domain and prevents inhibition of the RAS signaling pathway, 
promoting the formation of xenograft tumors in mice (Min et al., 2009). Mice are 
the ideal candidates with which to study certain diseases affecting humans, as 
our genomes are 95% similar (Jong & Maina, 2010). In order to further study the 
effects of this SNP in vivo, a knock-in (Ki) mouse line was developed wherein 
progeny carry an Arg152Gln substitution, corresponding to the Arg158Gln 
substitution found in humans. This mouse expresses a variant LOX-PP (LOX-
PPv) compared to wild type (WT) mice that express LOX-PP (Cueva & Kirsch, 
unpublished)1. 
To clarify the function of LOX-PPv in the formation of breast and other 
cancers, WT and Ki mice were treated with medroxyprogesterone and 7,12-
Dimethylbenz[a]anthracene (DMBA), a polycyclic aromatic hydrocarbon (PAH) 
and tumor formation was observed. DMBA has been demonstrated to lead to 
																																																								1	Unpublished	study	conducted	by	Dr.	Ana	de	la	Cueva	and	Dr.	Kathrin	H.	Kirsch	in	the	Biochemistry	Department	at	the	Boston	University	School	of	Medicine.	
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mammary gland tumors in mice. Tumors in these mice displayed up-regulation of 
oncogenic signaling pathways including elements of the Wnt signaling pathway, 
the prolyl isomerase Pin-1, and the NF-κB pathway (Currier et al., 2005). 
 
Leukemia, DMBA, and the Liver  
DMBA has also been demonstrated to induce, to a lesser degree, 
leukemia in rodents. As the leukemia develops, leukemic cells have been 
detected primarily within the liver and spleen (Huggins & Sugiyama, 1966). These 
mice also displayed a decrease in body weight and experience splenomegaly, 
often developing to the point where the liver is palpable from the outside 
(Huggins & Sugiyama, 1966). 
Hepatic biopsy and subsequent histological analysis is one technique for 
detecting leukemia. Histological and immunohistochemical examination of these 
organs allows for the visualization of the invasion of large blast cells in the 
hepatic sinusoids and in the red pulp or lymph follicles of the spleen. Leukemia-
positive results present with dense clusters of basophilic cells in the sinusoids or 
portal triangles of the liver (Huggins & Sugiyama, 1966). Additionally, the 
expression of Ki-67, a nuclear protein associated with cellular proliferation, has 
been identified as an important diagnostic and prognostic tool in many types of 
neoplasms (Niikura et al., 2014; Scholzen & Gerdes, 2000). It is indicative of a 
poor prognosis in patients with estrogen receptor (ER)-positive breast cancer 
(Niikura et al., 2014; Scholzen & Gerdes, 2000). These findings allow for the 
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investigation and analysis of the effect of LOX-PPv on leukemia and 
lymphoproliferative disease formation in WT and Ki mice via histological analysis 
and immunohistochemistry. 
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HYPOTHESES AND GOALS 
A Kaplan-Meier curve indicated that Ki mice treated with DMBA develop 
tumors earlier (50% of mice: Ki=16.5 weeks; WT=19 weeks) and are more likely 
to suffer from poor body condition in comparison to their WT counterparts (Cueva 
& Kirsch, unpublished)2. The majority of these mice (Ki=79.2%; WT=91.6%) 
developed breast cancer, but several other mice developed poor body conditions 
such as severe dermatitis, lung infections, or hepatomegaly without any 
explanation. As DMBA has been found to induce leukemia in mice (Huggins & 
Sugiyama, 1966), we hypothesized that the mice developing poor body 
conditions without explanation would show development of leukemia or 
lymphoma.  Furthermore, given the protective function of LOX-PP, we 
hypothesized that leukemia and lymphoma development, if present, would be 
enhanced in Ki mice expressing LOX-PPv compared to WT mice expressing 
functional LOX-PP.  
																																																								2	Unpublished	study	conducted	by	Dr.	Ana	de	la	Cueva	and	Dr.	Kathrin	H.	Kirsch	in	the	Biochemistry	Department	at	the	Boston	University	School	of	Medicine.	
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MATERIALS AND METHODS 
1. Materials and Reagents  
1.1 Microscope Slide Coating 
Chromium Potassium Sulfate Dodecahydrate   Alfa Aesar (36715) 
Gelatin           Sigma Aldrich (G-6650) 
Microscope slides      American Central Scientific Co. (FFP-001-010-F-1) 
 
1.2 Hematoxylin and Eosin Staining 
1N Hydrochloric Acid      American Bio (AB00831-01000) 
Ammonium Hydroxide      American Bio (AB02333-02500) 
Eosin            Sigma Aldrich (HT110132-1L) 
Graded ethanols (70%, 80%, 95%, 100%) 
Hematoxylin              Sigma Aldrich (GHS332-1L) 
Xylenes                    Fisher (UN1307) 
 
1.3 Immunohistochemistry Protocol 
 30% H2O2           Fisher (H325-100) 
 Brij-35 powder             Sigma Aldrich (P1254) 
 DAB Substrate Kit         Vector Laboratories (SK-4100) 
 Liquid Blocker Super Pap Pen              Daido Sangyo 
 Normal Goat Serum Blocking Solution      Vector Laboratories (S-1000) 
 Phosphate Buffered Saline, 10X Solution             Fisher (BP399-500) 
	13 
 Tri-sodium citrate (dehydrate)     American Bio (AB01918-05000) 
 Tween 20        American Bio (AB02038-00500) 
Vectastain ABC Kit         Vector Laboratories (PK-6100) 
 
2. Antibodies 
Biotinylated anti-rabbit IgG        Vector Laboratories (BA-1000) 
Ki-67 antibody               Thermoscientific (9106-S0) 
 
3. Buffers and Solutions 
Ammonia water. Add 1.57 ml ammonium hydroxide to 500 ml dH2O. 
Acidified ethanol. Add 5 ml concentrated HCl to 500 ml 70% EtOH. 
Cadenza Buffer. This is essentially a Tris-buffered saline with Brij, a non-ionic 
detergent, instead of Triton. First, make standard Tris buffer (0.1 M, pH 7.6). 
Then, add 1.0 g of Brij-35 powder per 1.0 L of 1X buffer. 
Sodium Citrate Buffer. (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) 
Mix 2.94 g tri-sodium citrate (dehydrate) in distilled water until dissolved and 
bring the total volume to 1000 mL. Adjust pH to 6.0 with 1N HCl. Add 0.5 mL of 
Tween 20 and mix well. This solution can be stored at room temperature for 3 
months or at 4°C for extended length.  
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4. Methods 
4.1. Coating Microscope Slides with Gelatin. This gelatin slide coating 
protocol coats microscope slides with a positive charge, allowing for stronger 
adhesion of negatively charged tissue sections. The following protocol is a 
modified version of an R&D Systems protocol (Protocol for the Preparation of 
Gelatin-coated Slides for Histological Tissue Sections, n.d.). 
Prepare the gelatin-coating solution by heating 1.0 L of deionized H2O to 
approximately 40°C (do not exceed 45°C) and dissolving 5.0 g of gelatin into it. 
When the gelatin dissolves, add 0.5 g of chromium potassium sulfate 
dodecahydrate. This reagent will positively charge the slides, thereby attracting 
negatively charged tissue. The solution is then filtered using filter paper and a 
funnel. This solution can be stored at 2-8°C until use, at which time it is 
recommended that the solution be filtered once more before coating the slides. 
Adjust to room temperature before filtering a second time. 
To begin coating the slides, place the microscope slides into glass slide 
holders. Dip the glass slide holders containing the histological slides into the 
gelatin-coating solution 3 to 5 times for approximately 5 seconds each time. 
Remove the slide holders containing the slides and then blot excess solution 
onto filter paper. The used gelatin solution can be saved and stored at 2-8°C for 
reuse. 
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Place slide holders containing the slides on filter paper and cover with 
paper towels. Let dry at room temperature for 48 hours. Dried slides can be put 
into boxes and stored at room temperature until use.  
4.2. Cutting Paraffin Sections. Tissue samples were harvested from mice and 
embedded in paraffin. Sectioning the samples and mounting them on microscope 
slides allows for staining and visualization of desired tissue with a light 
microscope. 
First obtain paraffin-embedded samples. To ensure clean cuts of the 
samples, place blocks of paraffin-embedded samples facedown on an ice tray 
that is covered with a wet paper towel. Let the samples sit on the ice tray for 
approximately 5 minutes before cutting. 
Prior to cutting, cut the sample with a straight razor into a pyramid shape. 
Attempt to align edges and leave them parallel to one another. At this time, also 
prepare a water bath at 46-48°C for floating sections. 1.0 L of tap water can be 
heated in microwave for 2 minutes and poured into water bath to expedite the 
process. Repeat as necessary to obtain desired level of water. 
Mount sample in the chuck of microtome, locking firmly into place. Then, 
mount blade in blade holder. Clean the blade with Q-tip soaked in Xylenes-
substitute and ensure blade is dry before beginning to cut. Set the blade angle to 
5°. Switch the lever on the right side of the microtome to unlocked position, 
allowing for movement of the chuck. Using the dial on the front of the microtome, 
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set the desired section thickness. For this experiment, liver sections were all cut 
at 5µm thickness. 
Using the handle on the left side of microtome, align the sample block with 
the blade. Trim the block, if necessary, so that each cut produces uniform 
sections of the sample. To ensure a clean and uniformly exposed section, first 
trim sections at 20µm thickness until even sections of the sample are being cut 
each time. Be sure to reset the thickness to 5µm when obtaining samples. 
Start sectioning. Use toothpicks to guide the unrolling of the sections. 
Place sections in water bath, carefully separating from toothpick to ensure the 
sample is not torn. Using gelatin coated slides (Method 4.1), sweep up samples 
from water bath. Label slides with sample type and number, sample thickness, 
and date. 
Potential issues that can arise during cutting: 
a. Sample is too curly: block is too cold. Warm with hot breath to 
smooth out the sections. 
a. Sample is rigid or tearing easily: block is too hot. Cover an 
icepack with a damp paper towel and apply to block for 1:00 
min.  
i. Alternatively, the blade can be too dirty or dull. Clean or 
replace blade, or move the blade. 
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4.3. H&E Staining. This H&E Staining method is based on Bonna Ith’s H&E 
Protocol, which was further revised by Dr. Matt Layne3. H&E staining allows for 
the visualization and discrimination of cell nuclei/chromatin, cytoplasm, collagen, 
and smooth muscle. It also allows for the visualization of basophilic cells such as 
lymphocytes that have infiltrated tissues and organs. 
To begin, deparaffinize the samples by placing the slides for 10-15 
minutes at 55-60°C in hybe oven or equivalent. Do not exceed 60°C. Samples 
are deparaffinized when the wax is melted and transparent. Rehydrate slides by 
dipping, sequentially, in the following reagents for the specified amount of time: 
Xylenes (5 minutes), Xylenes (5 minutes), 100% EtOH (2 minutes), 100% EtOH 
(2 minutes), 95% EtOH (2 minutes), 95% EtOH (2 minutes), 80% EtOH (2 
minutes), dH2O (2 minutes). 
Begin staining the slides by dipping, sequentially, in the following reagents 
for the specified amount of time: Hematoxylin (3-4 minutes), tap water (dip and 
drain), acid alcohol (2-3 dips or 5-10 seconds), tap water (dip and drain), 
ammonia water (8-10 dips or 40-50 seconds), tap water (dip and drain), 80% 
EtOH (2 minutes), Eosin (20-50 seconds).  
The samples can be checked under the light microscope for color 
intensity. If necessary, repeat back to hematoxylin and carry out the sequence 
once more. This is only possible prior to staining with Eosin reagent, so the 
samples should be checked prior to this point. Additionally, the time spent in 																																																								3	Dr.	Matthew	Layne	in	the	Biochemistry	Department	at	the	Boston	University	School	of	Medicine.	
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Eosin depends on the reagent’s freshness. It is easy to over-stain with Eosin, so 
the samples should be monitored carefully. 
Begin to dehydrate the slides by dipping, sequentially, in the following 
reagents for the specified amount of time: 95% EtOH (dip and drain), 95% EtOH 
(dip and drain), 100% EtOH (dip and drain), 100% EtOH (2 minutes), xylenes (5 
minutes), xylenes (5 minutes). 
Following dehydration, mount slides with permount:xylenes or other 
mounting media and allow the slides to dry in fume hood. 
 
4.4. Immunohistochemistry Protocol. Paraffin-embedded sections of mouse 
tissue are stained using the following immunohistochemistry protocol to visualize 
specific antigens present in the liver or on blood cells. This allows for the 
identification and classification of normal or abnormal tissues. As a general rule 
of thumb, prepare ~40 µl of solution for each outlined section to ensure full 
immersion of tissue section. 
To begin, deparaffinize and rehydrate the samples exactly as described in 
the H&E Staining protocol above (Method 4.3). While the samples are being 
rehydrated, place a beaker of 1.0 L water in microwave for 20 minutes or until 
boiling for the High Temperature Antigen Retrieval portion of the protocol. It is 
best to begin heating the water during the deparaffinization and rehydration steps 
to allow the water to be as hot as possible. After water has begun boiling, pour it 
into pressure cooker and seal shut to prevent cooling. Fill a Coplin jar or other 
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appropriately sized container with Na+-citrate buffer and microwave until the 
solution is boiling. It is crucial for High Temperature Antigen Retrieval that this 
solution is as hot as possible. Save this step until immediately before rehydration 
is done to ensure the solution does not cool. Place rehydrated samples into 
Coplin Jar or substitute vessel filled with hot Na+-citrate buffer and put Coplin Jar 
or substitute vessel, covered, in the boiling hot water in the pressure cooker for 
30 minutes. 
Remove the jar from pressure cooker and allow to cool to room 
temperature for 20-30 minutes. Drain jar of Na+-citrate buffer, disposing of 
solution in the appropriate waste container and then rinse slides with 1X PBS for 
5 minutes. 
 Remove moisture from slides using Kimwipe, but be sure to not remove 
the tissue section itself. Outline the tissue section with the Liquid Blocker Super 
Pap Pen. Draw one circle per antibody and negative control, each one with a 
diameter of ~1.0 inches. Allow 1 to 2 minutes for pen to dry.  
Incubate outlined sections with Cadenza buffer twice, first for 2 minutes 
and then for 3 minutes. Incubate sections in 3% H2O2 (100 µl 30% H2O2 for every 
900 µl of Cadenza buffer) at room temperature for 20 minutes. This step is done 
in order to block endogenous peroxidase activity and prevent non-specific 
background staining. Remove H2O2 and wash with Cadenza buffer twice, first for 
2 minutes and then for 3 minutes. Block the sections with 5% normal goat serum 
in Cadenza buffer for 45 minutes at room temperature in a staining box with 
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damp paper towels. This normal serum is chosen to match the species of the 
secondary antibody host. 
Remove the blocking serum and wash with Cadenza buffer twice, first for 
2 minutes and then again for 3 minutes. Incubate the sections with Ki-67 primary 
antibody overnight at 4°C, diluting in Cadenza buffer at a 1:250 dilution. Remove 
primary antibody and wash twice with Cadenza buffer, first for 2 minutes and 
then again for 3 minutes. Incubate sections with diluted secondary antibody in 
Cadenza buffer for 1 hour at room temperature (1:200 dilution). This secondary 
antibody should be a Biotinylated Anti-(Primary Antibody Host Species) IgG. 
About 30 minutes into incubation with the secondary antibody, begin preparing 
reagents for the Vectastain ABC Kit steps. 
Remove the secondary antibody and wash with Cadenza buffer twice, first 
for 2 minutes and then again for 3 minutes. Incubate the sections with Vectastain 
ABC Kit (100 µl Cadenza buffer + 1.0 µl reagent A + 1.0 µl reagent B) for 1 hour 
at room temperature. About 30 minutes into incubation, prepare reagents for the 
3,3’-diaminobenzidine (DAB) Substrate Kit step. Remove ABC Kit solution and 
wash twice with Cadenza buffer, first for 2 minutes and then again for 3 minutes. 
Incubate sections with DAB Substrate Kit (2.5 ml Cadenza buffer + 1 drop 
DAB Buffer (pH = 7.5) + 2 drops DAB substrate + 1 drop H2O2) in order to 
produce a brown reaction product in the presence of peroxidase enzyme. This 
enzyme reaction should be carefully monitored to observe color development 
and to minimize background from over-incubating. For the Ki-67 primary 
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antibody, it is suggested to let the reaction incubate for 6-8 minutes, or until 
noticeably brown. Reaction times vary for each antibody used, so this reaction 
must be monitored closely if another primary antibody is being used. 
Stop enzyme reaction by immersing slides in water for 5 minutes and then 
counterstain slides in Hematoxylin by dipping, sequentially, in the following 
reagents for the specified amount of time: Hematoxylin (3-4 minutes), tap water 
(dip and drain), acid alcohol (2-3 dips or 5-10 seconds), tap water (dip and drain), 
ammonia water (8-10 dips or 40-50 seconds), tap water (dip and drain). The 
samples can be checked under the light microscope for color intensity. If 
necessary, repeat back to hematoxylin and carry out the sequence once more.  
Proceed to dehydrate the samples by dipping, sequentially, in the 
following reagents for the specified amount of time: 80% EtOH (2 minutes), 95% 
EtOH (dip and drain). Mount slides with Cytoseal or with a Cytoseal:xylenes (1:1) 
solution and allow to dry in fume hood. 
 
4.5. Viewing Stained Tissue Under the Light Microscope. Stained, paraffin-
embedded tissue of interest was viewed under the light microscope after being 
mounted on the positively-charged microscope slides (Method 4.1). Both the 
H&E and immunohistochemistry stains can be examined under the light 
microscope.  
a. H&E Stained Tissue 
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Tissues stained with Hematoxylin and Eosin were viewed under the light 
microscope at 10X and 40X magnification. Liver sections were examined 
for infiltration of lymphocytes, observable as strongly basophilic cells that 
stained with hematoxylin. These cells are approximately 7.5-10 µm in size. 
Sections of tissue in which an abnormal aggregation of lymphocytes were 
observed were further examined to determine the number of clusters of 
lymphocytes viewable within the 10X magnification lens, with clusters 
being defined as a group of three or more lymphocytes.  
Following examination under the light microscope, livers were 
arbitrarily assigned to one of four classifications: normal, having possible 
lymphocyte infiltration, having mild lymphocyte infiltration, or as having 
massive lymphocyte infiltration. Normal livers displayed no obvious signs 
of lymphocyte infiltration and exhibited a normal morphological phenotype. 
Livers were classified as having possible lymphocyte infiltration if there 
appeared to be any sign of abnormal aggregations of basophilic cells, but 
only if these cells were unable to be confirmed as likely resembling 
lymphocytes. Livers were classified as having mild lymphocyte infiltration if 
there was an obvious sign of clusters of lymphocytic cells within the tissue. 
These clusters were observable in larger numbers than those found in 
livers classified as having possible lymphocyte infiltration. Livers observed 
as having massive lymphocyte proliferation had very noticeable infiltration 
of lymphocytes throughout the tissue, on the scale of greater than 200 
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(>200) clusters per field. These samples were given to a pathologist who 
diagnosed the affected mice with leukemia. 
b. Immunohistochemistry with Ki-67 Primary Antibody 
Tissues stained with the immunohistochemistry protocol using the Ki-67 
primary antibody were viewed under the light microscope at 10X and 40X 
magnification. The presence of Ki-67 is identifiable as single cells stained 
a deep brown color. Liver sections determined to be positive for the 
presence of Ki-67 were further examined under the 40X magnification lens 
and arbitrarily assigned to one of three classifications: normal, having mild 
expression of Ki-67 (+), or having massive expression of Ki-67 (+++). To 
determine the degree to which each section was Ki-67+, the number of Ki-
67+ cells per 40X objective field were counted by hand. 
 
4.6 Statistical Methods Used in Examination of Stained Tissue Sections. To 
ensure an accurate reading of H&E positive cell clusters and Ki-67-positive cells 
per objective field, multiple readings were taken from the stained tissue sections. 
Random portions of the liver were chosen for observation under the microscope 
by simply moving the microscope under the lens and stopping at a random 
location within the tissue. This was performed a total of three times (x1, x2, x3) for 
each tissue section. The average number of H&E positive cell clusters or Ki-67-
positive cells (NH&E and NKi-67, respectively) was then determined by the following 
equation: N = (x1 + x2 + x3) / 3.  This method ensures the most accurate reading 
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of the sample in regards to clusters of lymphocyte infiltration and number of Ki-
67+ cells.  
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RESULTS 
 
Analysis of liver sections for signs of leukemia and leukocyte infiltration 
 Of the twenty-four (24) mice treated in each group (Ki and WT), twenty-
three (23) Ki and twenty-three (23) WT were available for testing our hypotheses. 
Mouse liver sample #44 from the Ki mouse line was found to be unsuccessfully 
embedded and perfused in paraffin. In addition, one of the WT mice (#11) had 
not developed a tumor at the end of the study period and was thus not analyzed. 
None of the mice developed solid tumor metastases from the primary mammary 
gland tumor. The results of the stains are found in Table 1 and Table 2. Mice 
numbers labeled in red indicate mice that exhibited poor body conditions. 
 In the Ki mouse line, 7 (30.4%) mice showed poor body conditions, 
compared to 2 (8.7%) WT mice. Two of the KI mice with poor body condition 
suffered from severe dermatitis but for the other 5 mice no obvious cause for 
their poor health was observed. Four of those 5 Ki mice (80.0%) suffering from 
poor body conditions, but not from severe dermatitis, were examined by a 
pathologist, Dr. Shi Yang4, and found to have massive lymphocyte infiltration in 
the liver consistent with leukemia. The remaining mouse had an enlarged liver 
and thymus, and while lymphocyte infiltration was visible in the liver it was not 
elevated to the extent of the other animals.  
																																																								4	Dr.	Shi	Yang	of	the	Department	of	Pathology	and	Laboratory	Medicine	at	the	Boston	University	School	of	Medicine.	
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 In contrast, only one liver of the two WT mice with poor body conditions 
displayed what was classified as massive lymphocyte infiltration. This massive 
lymphocyte infiltration was consistent with leukemia as determined by Dr. Yang 
and for the second mouse leukemia/lymphoma diagnosis was also made by Dr. 
Yang and correlated with strong lymphocyte infiltration in lung tissue (Lim, 
unpublished)5. In conclusion, of the 9 total mice diagnosed with poor body 
condition, 6 (66.6%; 4 Ki and 2 WT) were diagnosed with leukemia/lymphoma. 
 In addition, of the remaining livers examined that did not have leukemia 
(19 Ki ; 21 WT) , 10 Ki mice out of 19 (52.6%) displayed abnormal lymphocyte 
infiltration in the liver but to a lesser degree. In comparison, only 5 WT mice out 
of 21 total (23.8%) displayed abnormal lymphocyte infiltration to a lesser degree 
in the liver following DMBA treatment. Within the abnormal classifications, 3 Ki 
mice (13.0%) had possible lymphocyte infiltration compared to 1 WT mouse 
(4.3%), 7 Ki mice (30.4%) had mild lymphocyte infiltration (Fig. 1B) compared to 
4 WT mice (17.4%). Of the 6 mice classified as having massive lymphocyte 
infiltration in both WT and Ki mice, 2 (33.3%) were classified as having portal 
lymphocyte infiltration (Fig. 1D) and 3 (50.0%) were classified as having 
sinusoidal lymphocyte infiltration (Fig. 1C) (Baumhoer, Tzankov, Dirnhofer, 
Tornillo, & Terracciano, 2008). One WT liver was not available for evaluation. 
Figure 2 displays the results of the Hematoxylin and Eosin staining in histogram 
form.   																																																								5	Sarah	Lim,	undergraduate	research	assistant	in	the	Kirsch	Lab	of	the	Boston	University	School	of	Medicine’s	Biochemistry	Department.		
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Figure 1. Livers stained with Hematoxylin and Eosin. a.) Liver sample from Ki 
mouse #969, not treated with DMBA (normal); b.) Liver sample from Ki mouse 
#17; mild lymphocyte infiltration. The arrows point to “clusters” of lymphocytes; 
c.) Liver sample from Ki mouse #21; massive sinusoidal lymphocyte infiltration; 
d.) Liver samples from Ki mouse #56; massive portal lymphocyte infiltration). 
Scale bar 100µm.  
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Table 1. Results of Hematoxylin and Eosin Staining of Ki Mouse Livers 
KI Available for H&E Analysis: 23 
Mouse No. (#) H&E Analysis Avg. H&E Clusters/10x field 
2 Normal  
4 Normal   
19 Normal   
23 Normal   
25 Normal   
45 Normal   
46 Normal   
48 Normal   
49 Normal   
7 Possible lymphocyte infiltration 3 
8 Possible lymphocyte infiltration 1 
26 Possible lymphocyte infiltration 1.67 
3 Mild lymphocyte infiltration 0.67 
5 Mild lymphocyte infiltration 6.33 
17 Mild lymphocyte infiltration 15.67 
24 Mild lymphocyte infiltration 2 
47 Mild lymphocyte infiltration 2.33 
58 Mild lymphocyte infiltration 1.33 
65 Mild lymphocyte infiltration 2.67 
6 Massive lymphocyte infiltration  >200 
15 Massive lymphocyte infiltration  >200 
21 Massive lymphocyte infiltration >200  
56 Massive lymphocyte infiltration >200  
44 Bad sample   
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Table 2. Results of Hematoxylin and Eosin Staining of WT Mouse Livers 
WT Available for H&E Analysis: 23 
Mouse No. (#) H&E Analysis Avg. H&E Clusters/10x field 
10 Normal   
13 Normal   
14 Normal   
29 Normal   
31 Normal   
34 Normal   
35 Normal   
36 Normal   
37 Normal   
38 Normal   
41 Normal   
50 Normal   
51 Normal   
61 Normal   
63 Normal   
64 Normal   
62 Possible lymphocyte infiltration 2.33 
9 Mild lymphocyte infiltration 4.67 
32 Mild lymphocyte infiltration 3.33 
42 Mild lymphocyte infiltration 6.67 
54 Mild lymphocyte infiltration 5 
12 Massive lymphocyte infiltration >200 
59 Massive lymphocyte infiltration  >200 
11 N/A N/A 
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Figure 2. Lymphocyte infiltration in livers in LOX-PP Ki vs. WT Mice after 
treatment with DMBA. This histogram displays the frequency with which mice 
were classified as normal or as having possible lymphocyte infiltration, 
lymphocyte infiltration, or massive lymphocyte infiltration.  
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Cell proliferation measured by Ki-67 Staining 
 Twenty-three (23) Ki and twenty-two (22) WT mouse livers were available 
proliferation analysis by immunohistochemistry with Ki-67 antibody. Also included 
in the Ki-67 analysis were 4 livers from normal mice not treated with DMBA as 
control samples, two of which are Ki and two of which are WT. Mouse liver 
sample #26 from the Ki mouse line and liver samples #11 and #12 from the WT 
mouse line were found to be unusable for this experiment. The results of the Ki-
67 primary antibody stain are found in Tables 3 and 4. 
 Of the 23 Ki mice livers stained with Ki-67, 14 (60.9%) displayed some 
degree of positivity for the expression of Ki-67, while 10 of the 22 WT mice livers 
(45.5%) were positive for the expression of Ki-67. Specifically, 3 of the 23 Ki mice 
livers (13.0%) were massively positive (+++) (Fig. 3B,D) for the expression of Ki-
67 while only 1 of the 22 WT mice livers (4.5%) was massively positive for Ki-67. 
Of the remaining samples, 11 (47.8%) Ki mice livers slightly positive (+) and 9 
(40.9%) WT mice livers were slightly positive (+) for the expression of Ki-67 (Fig. 
3C). Figure 4 displays the results of this experiment in histogram form.  
 In addition, five (5) of the 9 (55.5%) mice stated to have poor body 
condition tested positive for observable levels of Ki-67 expression. The four livers 
classified as massively positive for Ki-67 expression (3 Ki and 1 WT) correlate 
with mice that had been diagnosed with leukemia/lymphoma. Of the other two 
mice with leukemia that were not massively positive for Ki-67 expression, 1 was 
slightly positive for Ki-67 and the other was unavailable for analysis. 
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Table 3. Results of Ki-67 Antibody Immunohistochemistry of Ki Mice 
KI Available for Ki 67 analysis: 23 
Mouse No. (#) Ki67 Analysis Avg. Ki67+ Cells/40x field 
2 Negative 		
7 Negative 		
23 Negative 		
25 Negative 		
44 Negative 		
46 Negative 		
47 Negative 		
48 Negative 		
49 Negative 		
3 + 59 
4 + 56.7 
5 + 48 
8 + 7.67 
15 + 82.7 
17 + 85 
19 + 36.67 
24 + 12.33 
45 + 3.3 
58 + 7 
65 + 49.3 
6 +++ >200 
21 +++ >200 
56 +++ >200 
024 + 5 
969	 + 3 
26 N/A Bad sample 
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Table 4. Results of Ki-67 Antibody Immunohistochemistry of WT Mice 
WT Available for Ki67 analysis: 22 
Mouse No. (#) Ki67 Analysis Avg. Ki67+ Cells/40x field 
9 Negative   
10 Negative   
29 Negative   
32 Negative   
35 Negative   
38 Negative   
50 Negative   
51 Negative   
54 Negative   
61 Negative   
63 Negative   
64 Negative   
13 + 14.3 
14 + 7.7 
31 + 22.3 
34 + 10.3 
36 + 40.7 
37 + 18 
41 + 9.3 
42 + 36 
62 + 40.3 
59 +++ >200 
026 + 5 
684 + 8 
12 Bad Cut N/A 
11 N/A N/A 
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Correlation Between H&E and Ki-67 Positivity 
 Of the 4 Ki Mice livers classified as having “massive lymphocyte 
infiltration,” 3 (75.0%) were also classified as being massively positive (+++) for 
the presence of the Ki-67 antigen. For WT mice, there was a correlation between 
the massively positive expression of Ki-67 and “massive lymphocyte infiltration” 
as well, with sample number 59 identifying as massively positive for both 
lymphocyte infiltration and expression of Ki-67 antigen. In total, 4 (66.7%) of the 
6 mouse livers identified as having massive lymphocyte proliferation had a very 
positive expression of Ki-67 antigen. WT sample #12, a liver with massive 
lymphocyte infiltration, was unavailable for analysis using immunohistochemistry. 
It is likely that, if available, it would have also been massively positive for Ki-67 
expression. 
 In total, 18 Ki mouse livers were classified as positive for either 
lymphocyte proliferation or for the presence of the Ki-67 antigen. Of these, 11 
(61.1%) showed some degree of positivity for both lymphocyte proliferation and 
for the presence of Ki-67 antigen. For WT mouse livers, a total of 12 livers were 
classified as positive for either lymphocyte infiltration or for the presence of the 
Ki-67 antigen. Of these, 3 (25%) showed some degree of positivity for both 
lymphocyte infiltration and for the presence of Ki-67 antigen.  
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Figure 3. Livers stained with Ki-67 antibody. a.) Negative control; b.) Liver 
sample from Ki mouse sample #59, stained positive for Ki-67 expression; 
massively positive (+++). c.) Liver sample from Ki mouse sample #19, stained 
positive for Ki-67 expression; slightly positive (+). d.) Liver sample from Ki mouse 
sample #21, stained positive for Ki-67 expression; massively positive (+++). 
Scale bar: 100µm. The red arrows point to individual Ki-67+ cells. The black 
arrow points to a cluster of Ki-67+ cells. 
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Figure 4. Expression of Ki-67 in LOX-PP Ki vs. WT Mice after treatment with 
DMBA. This stacked column histogram displays the frequencies with which Ki 
and WT mice were classified as being slightly positive (slightly +) or as being 
massively positive (massively +++) for the expression of Ki-67 following 
treatment with DMBA. 
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DISCUSSION 
 
Knock-in and wild type mice were treated with DMBA and the formation of 
mammary gland tumors was observed. By the end of the study period, 79.2% of 
the Ki mice and 91.6% of the WT mice developed breast cancer. While a greater 
percentage of WT versus Ki mice ultimately developed breast cancer, Ki mice 
developed tumors more quickly and were more likely to suffer from poor body 
conditions than their WT counterparts. Ki mice represented 77.7% of the mice 
that suffered from poor body conditions (Cueva & Kirsch, unpublished)6. These 
findings corroborate those of Min et al. and others who have previously noted the 
importance of a functional LOX-PP in the attenuation of invasive and metastatic 
properties of breast cancer cells and xenograft growth in a mouse model and 
other cancers.  
Interestingly, a number of DMBA-treated mice suffering from poor body 
conditions showed no signs of having developed breast cancer. We 
hypothesized that these mice suffered from leukemia or some other 
lymphoproliferative disease and, in following with the work of Huggins et al., we 
focused our search for these diseases on the liver. Indeed, our analyses of H&E 
stained mouse livers showed abnormal lymphocyte infiltration characteristic of 
leukemia or other lymphoproliferative diseases in 60.9% of LOX-PP Ki mice and 
in 29.2% of WT mice livers. Following analysis by a pathologist, six of the mice (4 																																																								6	Unpublished	study	conducted	by	Dr.	Ana	de	la	Cueva	and	Dr.	Kathrin	H.	Kirsch	in	the	Biochemistry	Department	at	the	Boston	University	School	of	Medicine.	
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Ki and 2 WT) displaying abnormal lymphocyte infiltration were diagnosed with 
leukemia or lymphoma. These diagnoses correlated to those mice who suffered 
from poor body conditions but that were not diagnosed with breast cancer. That 
these mice were diagnosed with leukemia supports our hypotheses that 
unexplained poor body conditions would be due to leukemia or other 
lymphoproliferative diseases. Additionally, that 66.7% of all diagnosed leukemias 
were found in Ki mice harboring the LOX-PPv supports our hypothesis that, if 
present, leukemia or some other lymphoproliferative disease would be more 
present in Ki than in WT mice.  
Furthermore, our experiment demonstrated that KI mice were more likely 
to express the nuclear proliferation-associated protein Ki-67 than WT mice when 
exposed to DMBA (60.8% versus 41.7%, respectively). It was also noted that the 
expression levels of Ki-67 reached observable levels in 5 of the 9 (55.5%) mice 
with poor body conditions, which supports previous findings that Ki-67 is a 
cellular proliferation marker indicative of a negative patient prognosis (Niikura et 
al., 2014; Scholzen & Gerdes, 2000). 
In both Ki and WT mice, there did appear to be a similarity in the physical 
distribution of both the basophilic lymphocytes in H&E and Ki-67+ cells within the 
tissue, suggesting that the lymphocytes themselves could be expressing the 
nuclear proliferative signal. This observation is noticeable when comparing H&E 
staining and Ki-67 immunohistochemistry from Ki mouse sample #21 (Fig. 1C, 
Fig. 3D). Both figures display cells as evenly distributed throughout the hepatic 
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sinusoids. Additionally, preliminary comparisons of H&E staining and Ki-67 
immunohistochemistry from DMBA-treated mice have demonstrated similar 
findings, especially amongst livers in mice definitively diagnosed with leukemia.  
Despite these findings, however, our research does not appear to show an 
absolute correlation between the degree of positivity for lymphocyte infiltration in 
H&E and Ki-67 expression levels, as 12 total mice expressed observable levels 
of Ki-67 but had little or no visible lymphocyte cluster infiltration abnormalities 
found in H&E analyses. Additionally, in mice that do show positive readings for 
both H&E and expression of Ki-67, there does not appear to be a correlation 
between number of H&E clusters and number of Ki-67+ cells. This could be due, 
however, to the fact that Ki-67+ readings indicate mostly single cells as 
expressing the antigen. In contrast, a positive H&E reading for abnormal 
lymphocyte infiltration was scored by the presence of aggregates of 3 or more 
basophilic cells to test positive. These clusters were rarely or not seen to be 
positive for Ki-67. Thus, it is possible that abnormal lymphocyte infiltration was 
present and simply not scored in livers that tested positive for Ki-67 expression.  
Given the nature of H&E staining and the antibody used in our 
immunohistochemistry analysis, we are unable to say definitively that the 
abnormal lymphocyte infiltration present in the livers of mice not diagnosed by 
the pathologist as having leukemia are, indeed, indicative of early manifestations 
of leukemia or other lymphoproliferative diseases. Future research could be 
directed to the identification and classification of these basophilic and Ki-67+ cells 
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in order to more accurately diagnose the cause of these abnormalities 
discovered in the liver. This could be done by staining for an antigen specific to 
leukemic cells or by conducting blood tests. Unfortunately, blood was not 
extracted and preserved from these mice prior to their sacrifice and disposal. As 
Huggins and Sugiyama demonstrated, it is helpful in the analysis and diagnosis 
of leukemia to procure blood from the periphery for analysis of leukocyte count, 
hematocrit, hemoglobin, and smeared blood films. Coupled with a liver biopsy, 
this is the best way to detect leukemia (Huggins & Sugiyama, 1966). 
Our research has thus further established the importance of LOX-PP in 
the attenuation and propagation of cancer. In its absence, mice are noticeably 
more likely to develop and succumb to poor body conditions, show noticeable 
lymphocyte infiltration in the liver indicative of leukemia and other 
lymphoproliferative diseases, and display the cellular proliferation marker Ki-67. 
Our findings therefore suggest that LOX-PP is not only important in the 
attenuation of breast cancer, but that a malfunctioning LOX-PP could result in a 
greater likelihood of leukemia or some other lymphoproliferative disease.  
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EDUCATION 
Boston University School of Medicine, Boston, MA        09/14 – Present  
M.S. in Medical Sciences [expected 05/16] 
 
Boston College, Chestnut Hill, MA              09/10 – 05/14 
B.S. in Biology 
 
RESEARCH 
Boston University School of Medicine, Boston, MA        06/15 – Present 
Graduate Research Assistant 
• Conducted histological analyses on mice livers to observe the role of a 
variant lysyl oxidase propeptide (LOX-PPv) in DMBA-induced cancer 
development in mice 
 
Flaum Eye Institute, University of Rochester, Rochester, NY         06/13 – 09/13 
Lab Assistant 
• Conducted research on the dynamics of tear film breakup in patients 
diagnosed with dry-eye syndrome, specifically those afflicted with 
aqueous deficient dry eye or meibomian gland dysfunction 
• Learned proper laboratory protocols for clinical-trials and became 
familiarized with complex laboratory techniques like optical coherence 
tomography and thermal imaging 
 
Investigations in Molecular Cell Biology, Chestnut Hill, MA         06/11 – 12/11 
Student 
• Collected and analyzed series of data to study gene knockouts in 
mutated strains of Saccharomyces cerevisiae 
• Utilized a variety of laboratory techniques like PCR, gel 
electrophoresis, SDS-PAGE, and Western blots to restore strains to a 
functional phenotype 
 
VOLUNTEER EXPERIENCE 
Boston Medical Center bWell Center, Boston, MA             01/15 - 12/15 
Volunteer 
• Engaged in a variety of health and fitness activities with pediatrics 
patients for three hours every week 
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• Acted as a resource for pediatrics patients and their families to 
empower them with information necessary to make healthy lifestyle 
choices 
 
Peer Health Exchange, Chestnut Hill, MA             10/12 – 05/13 
Health Educator 
• Constructed fun, informative lesson plans on how to lead a healthy 
lifestyle and thereafter presented them to ninth graders in urban 
Boston schools 
• Collaborated with peers in weekly workshops to improve 
communication and teaching skills 
• Specialized in drug and alcohol education 
 
PROFESSIONAL EXPERIENCE 
Boston College Interactive Media, Chestnut Hill, MA           01/11 – 05/14 
Media Crew 
• Filmed and worked sporting events for Boston College’s Division I 
collegiate teams 
• Operated film cameras, scoreboard, and replay machine during 
events, and thereafter assisted in the production of post-game videos 
 
ADT Security Systems, Rochester, NY              05/12 – 08/12 
Outbound Representative 
• Dealt directly with ADT customers and assisted in the scheduling of 
appointments for security system maintenance 
 
CLUBS/ORGANIZATIONS 
Boston University MAMS Subcommittee, Boston, MA        03/15 - Present 
Committee Member/Social Media Representative 
• Acted as liaison between current MAMS students and faculty 
• Interacted with prospective MAMS students at open houses, on 
campus tours, and via email or other social media venues such as 
Student Doctor Network and FaceBook 
• Held monthly meetings with the director of the MAMS program to 
discuss upcoming program events and to bring student inquiries to the 
attention of the faculty 
